Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus

被引：0
|
作者：
Hussey, Elizabeth K.
Clark, Richard V.
Amin, Dipti M.
Kipnes, Mark S.
O'Connor-Semmes, Robin L.
O'Driscoll, Eilis C.
Leong, Jenny
Murray, Sharon C.
Dobbins, Robert L.
Nunez, Derek J.
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [41] Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers
    Stoch, S. Aubrey
    Zajic, Stefan
    Stone, Julie A.
    Miller, Deborah L.
    van Bortel, Lucas
    Lasseter, Kenneth C.
    Pramanik, Barnali
    Cilissen, Caroline
    Liu, Qi
    Liu, Lida
    Scott, Boyd B.
    Panebianco, Deborah
    Ding, Yu
    Gottesdiener, Keith
    Wagner, John A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (05) : 1240 - 1254
  • [42] Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
    Hussey, Elizabeth K.
    Kapur, Anita
    O'Connor-Semmes, Robin
    Tao, Wenli
    Rafferty, Bryan
    Polli, Joseph W.
    James, Charles D., Jr.
    Dobbins, Robert L.
    BMC PHARMACOLOGY & TOXICOLOGY, 2013, 14
  • [43] Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
    Elizabeth K Hussey
    Anita Kapur
    Robin O’Connor-Semmes
    Wenli Tao
    Bryan Rafferty
    Joseph W Polli
    Charles D James
    Robert L Dobbins
    BMC Pharmacology and Toxicology, 14
  • [44] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PSI-352938, A NOVEL NUCLEOTIDE POLYMERASE INHIBITOR FOR HCV, FOLLOWING SINGLE ASCENDING ORAL DOSES IN HEALTHY SUBJECTS
    Symonds, William
    Denning, Jill M.
    Albanis, Efsevia
    Wright, Robert
    Lai, Alexander
    Berrey, Michelle
    HEPATOLOGY, 2010, 52 (04) : 1219A - 1219A
  • [45] Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects
    Anderson, Matt S.
    Gilmartin, Jocelyn
    Cilissen, Caroline
    De Lepeleire, Inge
    Van Bortel, Luc
    Dockendorf, Marissa F.
    Tetteh, Ernestina
    Ancona, June K.
    Liu, Rachael
    Guo, Ying
    Wagner, John A.
    Butterton, Joan R.
    ANTIVIRAL THERAPY, 2015, 20 (04) : 397 - 405
  • [46] Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
    Chen, Hanjing
    Chen, Weili
    Li, Hui
    Xu, Hongrong
    Yuan, Fei
    Sheng, Lei
    Liu, Chao
    Lin, Pingping
    Yang, Mengjie
    Li, Xuening
    Liu, Yang
    Walker, Brittany Marie
    Gheyas, Ferdous
    Iwamoto, Marian
    Stoch, S. Aubrey
    Krishna, Rajesh
    ADVANCES IN THERAPY, 2021, 38 (07) : 3973 - 3985
  • [47] Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
    Hanjing Chen
    Weili Chen
    Hui Li
    Hongrong Xu
    Fei Yuan
    Lei Sheng
    Chao Liu
    Pingping Lin
    Mengjie Yang
    Xuening Li
    Yang Liu
    Brittany Marie Walker
    Ferdous Gheyas
    Marian Iwamoto
    S. Aubrey Stoch
    Rajesh Krishna
    Advances in Therapy, 2021, 38 : 3973 - 3985
  • [48] MODEL-BASED CHARACTERIZATION OF RENAL GLUCOSE REABSORPTION DYNAMICS IN RESPONSE TO DAPAGLIFLOZIN IN HEALTHY AND TYPE 2 DIABETES MELLITUS SUBJECTS.
    Kasichayanula, S.
    Hong, Y.
    Roy, A.
    Griffen, S. C.
    LaCreta, F. P.
    Boulton, D. W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S69 - S69
  • [49] Safety, tolerability, pharmacokinetics(PK) and pharmacodynamics(PD) of HSK31858,a novel DPP-1 inhibitor in healthy volunteers:a phase I clinical trial
    Hou, Jie
    Guan, Wei Jie
    Li, Fang Qiong
    Zeng, Wei Fang
    Liu, Han Mo
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [50] Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects
    Hara, Katsutoshi
    Takahashi, Naoki
    Wakamatsu, Akira
    Caltabiano, Stephen
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (06) : 410 - 418
12345